Jason Molitoris is an Oncology physician affiliated with University of Maryland, Baltimore. OpenAlex indexes 239 publications with 2,411 citations (h-index 26); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6565 N Charles St Ste 203
Baltimore, MD 212045805
Telephone
443-849-3760Registry record last updated 8 Feb 2019.
Clinical trials
- A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
Sponsor: University of Maryland, Baltimore
- Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
Sponsor: University of Maryland, Baltimore
- Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
Sponsor: University of Maryland, Baltimore
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Siemens Medical Solutions USA, Inc.Program year20255 payments
- Teleflex LLCProgram year20252 payments
- GE HEALTHCAREProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
65.2%alpha-Adrenergic Blocker65.2%Tamsulosin Hcl100%Part D≥27 patientsAnti-infectives
18.8%Short-acting sulfonamides18.8%Sulfamethoxazole-Trimethoprim100%Part D≥12 patientsSensory organs
15.9%Fluoroquinolone Antibacterial15.9%Ciprofloxacin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- SOX2 and OCT4 mediate radiation and drug resistance in pancreatic tumor organoids
Cell Death Discovery
2024 - Clinical Implementation and Dosimetric Evaluation of a Robust Proton Lattice Planning Strategy Using Primary and Robust Complementary Beams
International Journal of Radiation Oncology*Biology*Physics
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Kittner
University of Maryland, Baltimore
Edward Sausville, MD
University of Maryland, Baltimore
Aloke Finn, MD
University of Maryland, Baltimore
Christopher Plowe, MD
University of Maryland, Baltimore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”